Remdesivir (trade name Remdeform) was included in all inpatient treatment regiments in the 12th version of the temporary guidelines for the treatment of patients with COVID-19 approved by the Ministry of Health of the Russian Federation on September 21, as Pharmasintez, the manufacturer of the drug, reports.
“The change from the 11th version of the recommendations is that it has become possible to prescribe remdesivir to patients with a high comorbidity index who have a mild course of the disease and are treated in inpatient settings,” the report says.
It is noted that the section “Pathogenetic treatment” has been completely revised taking into account the accumulated experience of COVID-19 treatment: the information about possible combinations of drugs was added, including those that include remdesivir. The regimens for patients with moderate and severe course of the disease were revised: etiotropic therapy was optimized towards the use of more effective approaches (Remdesivir, human anti-COVID-19 immunoglobulin).
